Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Current Leases (2021 - 2025)

Sutro Biopharma (STRO) has disclosed Current Leases for 5 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 4.05% to $7.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Dec 2025, up 4.05% year-over-year, with the annual reading at $7.8 million for FY2025, 4.05% up from the prior year.
  • Current Leases hit $7.8 million in Q4 2025 for Sutro Biopharma, down from $8.0 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $8.1 million in Q2 2025 to a low of $1.0 million in Q4 2021.
  • Historically, Current Leases has averaged $5.3 million across 5 years, with a median of $6.3 million in 2023.
  • Biggest five-year swings in Current Leases: skyrocketed 429.82% in 2023 and later grew 4.05% in 2025.
  • Year by year, Current Leases stood at $1.0 million in 2021, then skyrocketed by 342.14% to $4.6 million in 2022, then skyrocketed by 40.02% to $6.4 million in 2023, then increased by 16.51% to $7.5 million in 2024, then grew by 4.05% to $7.8 million in 2025.
  • Business Quant data shows Current Leases for STRO at $7.8 million in Q4 2025, $8.0 million in Q3 2025, and $8.1 million in Q2 2025.